Aemetis (NASDAQ:AMTX - Get Free Report) had its target price raised by stock analysts at Ascendiant Capital Markets from $20.00 to $21.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the specialty chemicals company's stock.
Several other equities research analysts also recently issued reports on AMTX. Weiss Ratings reissued a "sell (e+)" rating on shares of Aemetis in a research note on Saturday, September 27th. UBS Group lifted their price objective on Aemetis from $2.20 to $3.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $17.33.
Get Our Latest Stock Analysis on Aemetis
Aemetis Stock Performance
Shares of NASDAQ AMTX opened at $2.65 on Monday. Aemetis has a 1 year low of $1.22 and a 1 year high of $4.73. The stock has a fifty day moving average price of $2.50 and a two-hundred day moving average price of $2.17. The firm has a market cap of $167.59 million, a P/E ratio of -1.64 and a beta of 1.68.
Aemetis (NASDAQ:AMTX - Get Free Report) last released its earnings results on Thursday, August 7th. The specialty chemicals company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The company had revenue of $52.24 million for the quarter, compared to analyst estimates of $78.68 million. On average, research analysts predict that Aemetis will post -2.07 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Francis P. Barton sold 26,452 shares of Aemetis stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $2.53, for a total transaction of $66,923.56. Following the completion of the transaction, the director directly owned 208,518 shares of the company's stock, valued at $527,550.54. This trade represents a 11.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On Aemetis
Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its position in Aemetis by 206.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 22,962 shares of the specialty chemicals company's stock valued at $57,000 after purchasing an additional 15,474 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Aemetis in the second quarter valued at about $42,000. Jane Street Group LLC acquired a new position in Aemetis during the 2nd quarter worth about $634,000. Qube Research & Technologies Ltd acquired a new stake in Aemetis in the 2nd quarter valued at about $246,000. Finally, Jump Financial LLC bought a new position in shares of Aemetis in the second quarter worth about $64,000. 27.02% of the stock is currently owned by institutional investors.
About Aemetis
(
Get Free Report)
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aemetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aemetis wasn't on the list.
While Aemetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.